<p>Disclosed is a CTL inducer composition which comprises at least one peptide selected from the group consisting of the peptides depicted in SEQ ID NO:1 to SEQ ID NO:27 in the Sequence Listing, and which can be used for the treatment or prevention of cancer or a disease associated with a hepatitis C virus in two or more groups of patients selected from the group consisting of a group of HLA-A2-positive patients, a group of HLA-A24-positive patients, a group of HLA-A26-positive patients and a group of HLA-A3 supertype-positive patients.</p>
